LY294002 | PI3K/AKT Pathway Inhibitor | STEMCELL Technologies
LY294002 is a PI3K inhibitor that has greater potency and selectivity than quercetin, the structure on which it is based. LY294002 inhibits PI3K (IC₅₀ = 1.4 µM) and also shows activity against CK2, but not PI4K, EGFR, PDGFR, MAPK, PKA, or PKC. (Davies et al., Vlahos et al.)
LY294002 | PI3K抑制剂 | MCE - MCE-生物活性分子大师
2019年7月27日 · LY294002 是一种广谱 PI3K 抑制剂，抑制 PI3Kα, PI3Kδ 和 PI3Kβ 的 IC50 分别为 0.5, 0.57, 0.97 μM。 LY294002 也可抑制 CK2 的活性， IC50 为 98 nM。 LY294002 是一种竞争性 DNA-PK 抑制剂，可逆结合 DNA-PK 的激酶结构域， IC50 为 1.4 μM。 LY294002 是一种凋亡 (apoptosis) 激活剂。 * Please select Quantity before adding items. • Signal Transduct Target Ther. 2022 Aug 31;7 (1):290. [Abstract]
LY294002 | Cell Signaling Technology
LY294002 was shown to act in vivo as a highly selective inhibitor of phosphatidylinositol 3 (PI3) kinase. When used at a concentration of 50 μM, it specifically abolished PI3 kinase activity (IC50=0.
PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT ...
LY294002 and wortmannin are chemical compounds that act as potent inhibitors of phosphoinositide 3-kinases (PI3Ks). Both of them are generally used to inhibit cell proliferation as cancer treatment by inhibiting the PI3K/protein kinase B (AKT) signaling pathway.
PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT ...
In this study, LY294002 (but not wortmannin) showed an abnormal ability to enhance AKT phosphorylation (at Ser472) specifically in gemcitabine (GEM)-resistant pancreatic cancer (PC) cell lines PK59 and KLM1-R. LY294002 was shown to activate AKT and accumulate phospho-AKT at the intracellular membrane in PK59, which was abolished by treatment ...
Phosphatidylinositol 3-kinase inhibitor(LY294002) induces …
2010年4月22日 · The dose (50 mg/kg and 75 mg/kg) of LY294002 produced obvious inhibition of Akt phosphorylation, reduced tumor cell proliferation, and increased apoptosis in orthotopic CNE-2Z NPC xenografts. Akt specific inhibitor, LY294002, did not cause obvious apoptosis at 24 h exposure, but induced greatly apoptosis in 48 h in a time-dependent manner.
PI3K/AKT 特异性抑制剂LY294002对卵巢癌化疗增敏作用的研究*
目的：探讨磷脂酰肌醇-3- 激酶（PI 3K）抑制剂LY294002对卵巢癌化疗效果的影响。 方法：将LY294002单独或与顺铂、紫杉醇联合作用于卵巢癌A2780、SKOV 3 细胞，MTT 法检测DDP 、顺铂单独或联合LY294002处理后对A2780、SKOV 3 细胞的抑制率；采用流式细胞技术检测药物单独或联合作用对A2780和SKOV 3 细胞凋亡的影响；应用Western blot检测A2780和SKOV 3细胞中AKT 及磷酸化AKT（p-AKT ）蛋白表达的变化。
The role of the nuclear Akt activation and Akt inhibitors in all-
2006年4月13日 · Before the synthesis of new pharmacological Akt-inhibitors, PI-3K inhibitor LY 294002 has been widely used to study the role of PI3K/Akt pathway. LY 294002 at a final concentration of...
LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, …
2006年12月1日 · Recently it was found that the phosphatidylinositol-3-kinase (PI3K/Akt) pathway inhibitor LY294,002 blocks drug transport from HT29RDB colon carcinoma cells overexpressing MRP1 protein (Abdul-Ghani et al., 2006). The potentiation of doxorubicin-induced apoptosis was connected with increased drug accumulation, blocking of Akt kinase ...
LY‑294002 enhances the chemosensitivity of liver cancer to …
Abnormal activation of the PI3K/AKT pathway plays an important role in the acquired resistance of oxaliplatin. The present study investigated the effects of the PI3K inhibitor LY‑294002 and AKT inhibitor MK2206 on the chemosensitivity of oxaliplatin‑resistant liver cancer cells and the molecular mechanism involved.